Standard BioTools Inc. (LAB)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 1
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are below the required floor of 3, and LAB also fails the strategy's liquidity floor with avgDollarVolume20 of just $1.35M.
Company overview
Standard BioTools Inc. develops, manufactures, and sells instrumentation, consumables, and services for scientists and biomedical researchers globally. The company operates through its Proteomics and Genomics segments, offering products like the SomaScan platform and CyTOF technology for clinical and diagnostic applications. It serves academic institutions, research centers, and biopharmaceutical companies.
Fundamental
weakThe company is cash-rich but remains deeply unprofitable with ongoing cash burn and strategic uncertainties.
Standard BioTools has strong liquidity following the SomaScan divestiture (the latest SEC filing shows cash and short-term investments in the hundreds of millions and a current ratio around 9x), and filings do not indicate an explicit going-concern warning. However, the core business is still sharply unprofitable (TTM net margin roughly -103%) with continued negative free cash flow, and recent quarters show revenue softness. With the pending Treeline merger and Nasdaq listing-compliance risk from a sub-$1 share price, the fundamentals support a cautious watch-and-wait stance despite an optically low EV/Sales multiple.
Sentiment
weakMedia sentiment has turned negative following Q2 results and guidance withdrawal, with no immediate catalysts for improvement.
Over the last two weeks, coverage has skewed negative after Q2 results (revenue down and FY2026 guidance withdrawn) while the Treeline reverse-merger remains an unresolved strategic overhang. Media sentiment deteriorated sharply versus the prior 30–90d merger-announcement baseline (polarity_score ≈ +0.59 → ≈ -0.25); moderate red-flag cap applied, and legal screens show only law-firm solicitation noise (no regulator-confirmed investigations).
Technical
very weakThe stock is in a strong downtrend, trading below key moving averages with oversold conditions persisting.
LAB trades below all major moving averages and below daily VWAP, MACD is negative and below its signal line, and ADX 38.21 confirms a strong trend that is currently down; RSI 35.74 and Williams %R -96.5 show oversold conditions, but not a confirmed bullish reversal.
You’re looking at 2026-08-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.